« Return to News | CROs/Service Providers

ICON Reports Growth in Revenues, Income and EPS

Thursday, July 23, 2009 06:59 AM

Dublin, Ireland-based ICON gave shareholders a triple dose of good news yesterday with its second quarter 2009 earnings release. Revenues, income and earnings per share were all up compared to last year.  Net revenues increased $1.7 million to $220 million and net income jumped $4 million to $22.8 million or 38 cents per share on a diluted basis.

Year-to-date net revenues were $439.8 million, a 5% increase compared with the same period last year, and year-to-date income was $56.2 million compared to $45.9 million last year. The CRO’s net cash as of June 30 was $83.2 million, compared to a net debt of $2.2 million last quarter.

“In the current market, we are pleased with the results for the quarter,” said CEO Peter Gray in a statement. “We continue to expand margin and as a result we increased operating income by 20% compared to the same period last year. In addition we are now amending guidance for revenue for the remainder of 2009 to $880 to $900 million and firming our EPS guidance, before one-time net charges to, $1.38 to $1.44.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.